CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 53 enrolled
Drug / intervention
Cediranib Maleate +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01132820
NCT01132820Phase 2Completed
CompareCT.gov

A Phase II Evaluation of Cediranib (Recentin; AZD2171, IND#72740, NSC# 732208) in the Treatment of Recurrent or Persistent Endometrial Carcinoma

National Cancer Institute (NCI)·interventional·Posted May 28, 2010·Updated Aug 8, 2019

In Brief

A Phase 2 clinical trial evaluating Cediranib Maleate and Laboratory Biomarker Analysis for Endometrial Adenocarcinoma and 4 related conditions. Completed, enrolled 53 participants across 87 sites.

Detailed Summary

This phase II trial studies the side effects and how well cediranib maleate works in treating patients with endometrial cancer that has failed to respond to initial chemotherapy or has come back after surgery, radiation therapy, or other forms of treatment. Cediranib maleate may stop the growth of tumor cells by blocking proteins made by tumors that can stimulate growth of tumor cells as well as blood vessels in and around tumors.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsEndometrial Adenocarcinoma, Endometrial Adenosquamous Carcinoma, Endometrial Clear Cell Adenocarcinoma, Endometrial Serous Adenocarcinoma, Recurrent Uterine Corpus Carcinoma
CountriesUnited States
CollaboratorsNRG Oncology

Timeline

Phase 2CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedMay 28, 2010
Enrollment StartJun 1, 2010
Primary CompletionJan 1, 2016
TodayJul 2, 2026
Enrollment to primary: 5.6 yearsPosted 16.1 years ago

Interventions

Cediranib Maleatedrug

Given PO

Laboratory Biomarker Analysisother

Correlative studies